These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 3404024)

  • 41. Systemic beta-interferon therapy for recurrent gliomas: a brief report.
    Mahaley MS; Dropcho EJ; Bertsch L; Tirey T; Gillespie GY
    J Neurosurg; 1989 Nov; 71(5 Pt 1):639-41. PubMed ID: 2809717
    [TBL] [Abstract][Full Text] [Related]  

  • 42. T-cell immunotherapy for malignant glioma: toward a combined approach.
    Dietrich PY; Dutoit V; Tran Thang NN; Walker PR
    Curr Opin Oncol; 2010 Nov; 22(6):604-10. PubMed ID: 20739889
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Peptide vaccination therapy for malignant glioma].
    Yamanaka R; Itoh K
    Brain Nerve; 2007 Mar; 59(3):251-61. PubMed ID: 17370651
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differential effects of combined Ad5- delta 24RGD and radiation therapy in in vitro versus in vivo models of malignant glioma.
    Lamfers ML; Idema S; Bosscher L; Heukelom S; Moeniralm S; van der Meulen-Muileman IH; Overmeer RM; van der Valk P; van Beusechem VW; Gerritsen WR; Vandertop WP; Dirven CM
    Clin Cancer Res; 2007 Dec; 13(24):7451-8. PubMed ID: 18094429
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cell- and peptide-based immunotherapeutic approaches for glioma.
    Yamanaka R
    Trends Mol Med; 2008 May; 14(5):228-35. PubMed ID: 18403264
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Malignant central nervous system tumors are susceptible to specific antibodies].
    Blizniukov OP; Kozmin LD; Oliushin VE; Ostreĭko OV; Filatov MV
    Vopr Onkol; 2001; 47(1):49-51. PubMed ID: 11317535
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Regression of orthotopic brain tumors by cytokine-assisted tumor vaccines primed in the brain.
    Tseng SH; Hsieh CL; Lin SM; Hwang LH
    Cancer Gene Ther; 1999; 6(4):302-12. PubMed ID: 10419048
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antitumor effect of recombinant murine interferon-beta against mouse malignant glioma.
    Kuroki M; Tanaka R; Suzuki Y; Moriyama M; Kuwabara Y; Kobayashi S
    J Interferon Res; 1987 Jun; 7(3):301-11. PubMed ID: 3497213
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Chemical modifiers in radiotherapy].
    Nagashima T; Takakura K
    Gan No Rinsho; 1989 Sep; 35(11):1369-71. PubMed ID: 2681875
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Dendritic cell therapy for malignant glioma].
    Yamanaka R; Homma J; Yajima N; Tsuchiya N; Tanaka R
    No To Shinkei; 2003 Sep; 55(9):771-80. PubMed ID: 14571839
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New therapeutic approaches to treatment of malignant gliomas: chemotherapy and immunotherapy.
    Mahaley MS; Gillespie GY
    Clin Neurosurg; 1983; 31():456-69. PubMed ID: 6680086
    [No Abstract]   [Full Text] [Related]  

  • 52. Selective radiosensitization of 9L glioma in the brain transduced with double suicide fusion gene.
    Kim JH; Kolozsvary A; Rogulski K; Khil MS; Brown SL; Freytag SO
    Cancer J Sci Am; 1998; 4(6):364-9. PubMed ID: 9853135
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Interferon therapy for primary brain tumors (Part I). Local administration].
    Nakagawa Y
    Neurol Med Chir (Tokyo); 1984 Feb; 24(2):83-9. PubMed ID: 6205292
    [No Abstract]   [Full Text] [Related]  

  • 54. [Interferon therapy for primary brain tumors (Part II). DNA analysis and mean survival time].
    Nakagawa Y
    Neurol Med Chir (Tokyo); 1984 Feb; 24(2):90-6. PubMed ID: 6205293
    [No Abstract]   [Full Text] [Related]  

  • 55. Local administration of human fibroblast interferon (Hu IFN-beta) for metastatic brain tumor.
    Kawakami Y; Chikama M; Tamiya T; Watanabe Y; Shimamura Y; Tsutsumi A; Chihara T
    Neurol Med Chir (Tokyo); 1988 Jul; 28(7):635-41. PubMed ID: 2462168
    [No Abstract]   [Full Text] [Related]  

  • 56. [rInterferon-alpha A (Ro 22-8181) therapy for patients with malignant brain tumors].
    Otsuka S; Yamashita J; Keyaki A; Handa H
    Gan To Kagaku Ryoho; 1984 May; 11(5):1084-91. PubMed ID: 6326684
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Clinical trials of human fibroblast interferon (Hu IFN-beta) on malignant brain tumors].
    Nagai M
    Nihon Gan Chiryo Gakkai Shi; 1983 Feb; 18(1):60-8. PubMed ID: 6345698
    [No Abstract]   [Full Text] [Related]  

  • 58. Pharmacokinetics of recombinant interferon-alpha 2 following intralesional administration in malignant glioma patients.
    Maleci A; Antonelli G; Guidetti B; Dianzani F
    J Interferon Res; 1987 Feb; 7(1):107-9. PubMed ID: 3585078
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of human leukocyte interferon on malignant brain tumors.
    Hirakawa K; Ueda S; Nakagawa Y; Suzuki K; Fukuma S; Kita M; Imanishi J; Kishida T
    Cancer; 1983 Jun; 51(11):1976-81. PubMed ID: 6839290
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunotherapy of patients with glioma: fact, fancy, and future.
    Mahaley MS; Gillespie GY
    Prog Exp Tumor Res; 1984; 28():118-35. PubMed ID: 6484196
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.